CC
OCUL icon

Centiva Capital’s Ocular Therapeutix OCUL Stock Holding History

Centiva Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Hold
25,000
– – ﹤0.01% 1288
2026
Q1 		$212K Buy
+25,000
New +$238K ﹤0.01% 1247

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Centiva Capital's OCUL Position: Q2 2026 in Review

Centiva Capital reduced its Ocular Therapeutix (OCUL) stake by 12% in Q2 2026, selling an estimated $27K and leaving 22,024 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Centiva Capital first reported a position in OCUL in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.92M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Centiva Capital held 22,024 shares of Ocular Therapeutix worth $216K as of Q2 2026.
  • Centiva Capital sold 2,976 Ocular Therapeutix shares in Q2 2026, an estimated $27K.
  • Ocular Therapeutix made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1366 holding.
  • Centiva Capital first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 4 quarters since.
  • Centiva Capital's Ocular Therapeutix position peaked at $2.92M in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.